Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Lenvatinib/tislelizumab

Extragenital giant condyloma acuminatum secondary to the severe immune disorder following pharmacodynamic interaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is: Drug interaction
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chi C-C, et al. Extragenital giant condyloma acuminatum in a hepatocellular carcinoma patient treated with lenvatinib plus PD-1 inhibitor. International Journal of Dermatology 62 : 1423-1424, No. 11, Nov 2023. Available from: URL: https://doi.org/10.1111/ijd.16757 Chi C-C, et al. Extragenital giant condyloma acuminatum in a hepatocellular carcinoma patient treated with lenvatinib plus PD-1 inhibitor. International Journal of Dermatology 62 : 1423-1424, No. 11, Nov 2023. Available from: URL: https://​doi.​org/​10.​1111/​ijd.​16757
Metadaten
Titel
Lenvatinib/tislelizumab
Extragenital giant condyloma acuminatum secondary to the severe immune disorder following pharmacodynamic interaction: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49608-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Azd-1222

Case report

Tozinameran

Case report

Ipilimumab

Case report

Dimeticone

Case report

Multiple drugs